Xiangyu Pharmaceutical Co., Ltd.

Main study objectives A randomized, open, two-treatment, two-period crossover design was used to evaluate the oral bioequivalence of clozapine tablets (specification: 25 mg) produced by Renhetang Pharmaceutical Co., Ltd. and clozapine tablets (specification: 25 mg, trade name: Clozaril®) certified by HERITAGE LIFE SCIENCES BARBADOS INC in Chinese schizophrenia subjects, and to provide evidence for the consistency of clinical efficacy between clozapine tablets produced by Renhetang Pharmaceutical Co., Ltd. and clozapine tablets certified by HERITAGE LIFE SCIENCES BARBADOS INC. Secondary study objectives Observe the safety of the test preparation clozapine tablets and the reference preparation clozapine tablets in subjects.

A single-center, randomized, open, two-period, self-crossover, single-dose design was used to compare the differences in absorption extent and rate in healthy people between the ibuprofen suspension (specification: 100 mL: 2 g) provided by Xiangyu Pharmaceutical Co., Ltd. and the ibuprofen suspension (trade name: Motrin®, specification: 100 ml: 2 g) produced by Shanghai Johnson & Johnson Pharmaceuticals Co., Ltd. under fasting and postprandial administration conditions, to evaluate the bioequivalence of the two preparations, and to evaluate the safety of the ibuprofen suspension provided by Xiangyu Pharmaceutical Co., Ltd.

This study investigated the pharmacokinetic characteristics of a single oral administration of isosorbide mononitrate tablets produced by Renhetang Pharmaceutical Co., Ltd. (test preparation, specification: 20 mg) or isosorbide mononitrate tablets certified by LANNETT CO INC (reference preparation, specification: 20 mg) under fasting and postprandial conditions, evaluated the bioequivalence between the two preparations, and provided a basis for the consistency evaluation of the test preparation.